Al's Comment:

 This drug is a new class called "immune transduction modifiers" and targets 3 important markers: STAT3, HIF1-a and c-Myc as well as JAK2..  Will keep an eye on this one. There is a clinical trial in Texas:   https://clinicaltrials.gov/ct2/show/NCT01904123

---

Posted on: 02/05/2019

Moleculin Biotech (MBRX) Announces FDA Orphan Drug Designation for its Brain Tumor Drug

 

---

Click HERE to return to brain tumor news headlines.